Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.44 |
| ▸ | CTSB | P07858 | 18/20 | 0.44 |
| ▸ | CTSD | P07339 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118327 | 1.00 | BACE1 (0.44) | BACE1CTSBCTSD | |
| SCHEMBL5124237 | 0.97 | BACE1 (0.43) | BACE1CTSBCTSD | |
| SCHEMBL5124225 | 0.97 | BACE1 (0.43) | BACE1CTSBCTSD | |
| SCHEMBL5122431 | 0.89 | BACE1 (0.46) | BACE1CTSBCTSD | |
| SCHEMBL5122420 | 0.89 | BACE1 (0.46) | BACE1CTSBCTSD | |
| SCHEMBL3352908 | 0.89 | BACE1 (0.46) | BACE1CTSBCTSD | |
| SCHEMBL3352919 | 0.89 | BACE1 (0.46) | BACE1CTSBCTSD | |
| SCHEMBL5119108 | 0.88 | BACE1 (0.45) | BACE1CTSBCTSD | |
| SCHEMBL5119102 | 0.88 | BACE1 (0.45) | BACE1CTSBCTSD | |
| SCHEMBL3915325 | 0.87 | BACE1 (0.48) | BACE1CTSBCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096942-A1 | Substituted Hydroxyethylamines | ELAN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | claimed |
| US-20040044072-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | claimed |
| US-20080096942-A1 | Substituted Hydroxyethylamines | ELAN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7312360-B2 | Substituted hydroxyethylamines | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1453788-A1 | SUBSTITUTED HYDROXYETHYLAMINES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040044072-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003050073-A1 | SUBSTITUTED HYDROXYETHYLAMINES | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096942-A1 | Substituted Hydroxyethylamines | BACE1, BACE2, MME | BACE1 1/4885CTSB 171/4885CTSD 409/4885 |
| US-20040044072-A1 | Substituted hydroxyethylamines | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSB 157/4885CTSD 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.